Compare Stocks → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GYRENASDAQ:HOOKNASDAQ:OCUPNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$11.36+9.1%$15.15$3.15▼$30.40$971.39M2.1353,910 shs178,489 shsHOOKHookipa Pharma$0.79+5.3%$0.81$0.41▼$1.40$78.57M0.92743,421 shs333,979 shsOCUPOcuphire Pharma$1.68$1.79$1.50▼$4.58$43.55M0.39157,375 shs51,597 shsVERUVeru$1.01+4.1%$1.22$0.36▼$1.92$147.85M-0.471.92 million shs1.88 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics0.00%-5.25%-19.43%-44.80%+1,135,999,900.00%HOOKHookipa Pharma0.00%-0.75%-13.50%+3.10%-39.39%OCUPOcuphire Pharma0.00%-4.55%-9.19%-33.60%-56.48%VERUVeru0.00%-17.89%-38.41%+57.81%+2.02%The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGYREGyre Therapeutics0.4283 of 5 stars0.03.00.00.03.10.80.6HOOKHookipa Pharma2.1221 of 5 stars3.53.00.00.02.11.70.6OCUPOcuphire Pharma2.3777 of 5 stars3.61.00.00.03.31.71.3VERUVeru1.5364 of 5 stars3.41.00.00.02.23.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre TherapeuticsN/AN/AN/AN/AHOOKHookipa Pharma3.00Buy$4.67487.74% UpsideOCUPOcuphire Pharma3.20Buy$18.751,016.07% UpsideVERUVeru2.80Moderate Buy$4.00296.04% UpsideCurrent Analyst RatingsLatest VERU, OCUP, HOOK, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.005/14/2024VERUVeruB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/13/2024OCUPOcuphire PharmaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2024OCUPOcuphire PharmaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $18.005/13/2024OCUPOcuphire PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/13/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/6/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $3.004/26/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.50 ➝ $5.004/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.003/28/2024VERUVeruRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$113.45M8.56$0.25 per share45.67$1.04 per share10.92HOOKHookipa Pharma$20.13M3.90N/AN/A$1.06 per share0.75OCUPOcuphire Pharma$19.05M2.29N/AN/A$1.78 per share0.94VERUVeru$16.30M9.07N/AN/A$0.31 per share3.26Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics-$92.93MN/A0.00N/AN/AN/A-730.65%-124.94%8/12/2024 (Estimated)HOOKHookipa Pharma-$81.58M-$0.50N/AN/AN/A-88.73%-33.33%-20.22%8/8/2024 (Estimated)OCUPOcuphire Pharma-$9.99M-$0.49N/AN/AN/A-59.44%-24.57%-22.22%8/9/2024 (Estimated)VERUVeru-$93.15M-$0.34N/AN/AN/A-265.27%-130.13%-67.82%8/8/2024 (Estimated)Latest VERU, OCUP, HOOK, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/10/2024Q1 2024OCUPOcuphire Pharma-$0.18-$0.29-$0.11-$0.29$3.01 million$1.71 million5/9/2024Q1 2024GYREGyre TherapeuticsN/A$0.04+$0.04$0.05N/A$27.17 million5/9/2024Q1 2024HOOKHookipa Pharma-$0.12$0.12+$0.24$0.13$3.20 million$36.60 million5/8/2024Q2 2024VERUVeru-$0.05-$0.07-$0.02-$0.07$3.00 million$4.14 million4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 million3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/8/2024Q4 2023OCUPOcuphire Pharma-$0.07-$0.21-$0.14-$0.21$3.47 million$1.69 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/AOCUPOcuphire PharmaN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A3.222.97HOOKHookipa PharmaN/A4.504.50OCUPOcuphire PharmaN/A8.968.96VERUVeruN/A4.724.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%HOOKHookipa Pharma63.88%OCUPOcuphire Pharma14.97%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics2.92%HOOKHookipa Pharma3.30%OCUPOcuphire Pharma8.70%VERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics59385.51 million83.01 millionNo DataHOOKHookipa Pharma5698.95 million95.69 millionOptionableOCUPOcuphire Pharma1425.92 million23.67 millionOptionableVERUVeru189146.38 million125.60 millionOptionableVERU, OCUP, HOOK, and GYRE HeadlinesRecent News About These CompaniesMay 28, 2024 | bovnews.comIt’s an all-out bull run for Veru Inc (VERU) StockMay 27, 2024 | pharmiweb.comFuture of Contraceptives: Market Valued at $26.3 Billion in 2020, Expected to Reach $50.6 Billion by 2030May 27, 2024 | marketbeat.comAIGH Capital Management LLC Purchases New Stake in Veru Inc. (NASDAQ:VERU)May 26, 2024 | americanbankingnews.comMitchell Shuster Steiner Sells 63,379 Shares of Veru Inc. (NASDAQ:VERU) StockMay 25, 2024 | insidertrades.comInsider Selling: Veru Inc. (NASDAQ:VERU) CEO Sells 63,379 Shares of StockMay 25, 2024 | bovnews.comWhere are Investors’ Sentiments? Veru Inc (VERU) StockMay 24, 2024 | marketbeat.comVeru Inc. (NASDAQ:VERU) CEO Sells $77,956.17 in StockMay 22, 2024 | finance.yahoo.comIndividual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%May 22, 2024 | globenewswire.comVeru to Present at the Jefferies Global Healthcare ConferenceMay 20, 2024 | marketbeat.comWorth Venture Partners LLC Invests $616,000 in Veru Inc. (NASDAQ:VERU)May 20, 2024 | lutontoday.co.ukA&E Navigators at Luton and Bedford hospitals help young people facing violenceMay 18, 2024 | insidertrades.comMitchell Shuster Steiner Sells 28,066 Shares of Veru Inc. (NASDAQ:VERU) StockMay 17, 2024 | investing.comVeru Inc. CEO sells over $246k in company stockMay 17, 2024 | investing.comVeru Inc. executive buys $9,999 in company stockMay 16, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Veru Inc.'s Q3 2024 Earnings (NASDAQ:VERU)May 15, 2024 | globenewswire.comVeru Announces Steven B. Heymsfield M.D.May 14, 2024 | globenewswire.comVeru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology WeekMay 14, 2024 | marketbeat.comB. Riley Initiates Coverage on Veru (NASDAQ:VERU)May 14, 2024 | markets.businessinsider.comBuy Rating for Veru Inc. on Promising Enobosarm Trials and Strategic Market PositioningMay 13, 2024 | bovnews.comIt’s Better to Hope for Prosperity than Become Adversary: Veru Inc (VERU) StockMay 13, 2024 | marketbeat.comVeru's (VERU) Buy Rating Reiterated at HC WainwrightNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGyre TherapeuticsNASDAQ:GYREGyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Hookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Ocuphire PharmaNASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.